Rivers Zachary T, Oostra Drew R, Westholder James S, Vercellotti Gregory M
1 Department of Pharmacy, University of Minnesota Medical Center, Minneapolis, MN, USA.
2 Department of Pharmaceutical Care and Health Systems, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA.
J Oncol Pharm Pract. 2018 Jan;24(1):56-62. doi: 10.1177/1078155216673229. Epub 2016 Oct 5.
Background Romidepsin is a novel histone deacetylase inhibitor that is approved for the treatment of cutaneous and peripheral T-cell lymphoma in patients who have had at least one prior therapy. Romidepsin is generally well tolerated, though it comes with a risk of cardiac toxicities. Objective We report a case of electrocardiogram changes in a 64-year-old male with enteropathy-associated T-cell lymphoma, type 2, treated with salvage romidepsin therapy who relapsed after non-myeloablative allogeneic sibling peripheral blood stem cell transplant. Discussion Although histone deacetylase inhibitors have been investigated for many years, they have only recently been translated to clinical use as a therapy for malignancies. Furthermore, given their approval for a rare disease, clinicians often have limited experience with the dosing and side effects of histone deacetylase inhibitors. Conclusion This case report and literature review investigates the cardiac side effects of histone deacetylase inhibitors and illustrates the importance of cardiac monitoring prior to and during treatment.
罗米地辛是一种新型组蛋白去乙酰化酶抑制剂，已被批准用于治疗至少接受过一种先前治疗的皮肤和外周T细胞淋巴瘤患者。罗米地辛一般耐受性良好，不过存在心脏毒性风险。
我们报告一例64岁男性肠病相关T细胞淋巴瘤2型患者，在非清髓性异基因同胞外周血干细胞移植后复发，接受挽救性罗米地辛治疗时出现心电图改变的病例。
尽管组蛋白去乙酰化酶抑制剂已研究多年，但直到最近才被转化用于临床治疗恶性肿瘤。此外，鉴于其被批准用于一种罕见疾病，临床医生对组蛋白去乙酰化酶抑制剂的给药和副作用往往经验有限。
本病例报告和文献综述研究了组蛋白去乙酰化酶抑制剂的心脏副作用，并说明了治疗前和治疗期间进行心脏监测的重要性。
